Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

KYMR

Kymera Therapeutics (KYMR)

Kymera Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KYMR
DateTimeSourceHeadlineSymbolCompany
05/14/20249:00AMGlobeNewswire Inc.Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
05/08/20246:00AMGlobeNewswire Inc.Kymera Therapeutics to Participate in Upcoming May Investor ConferencesNASDAQ:KYMRKymera Therapeutics Inc
05/02/20246:00AMGlobeNewswire Inc.Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:KYMRKymera Therapeutics Inc
04/25/20246:00AMGlobeNewswire Inc.Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2NASDAQ:KYMRKymera Therapeutics Inc
04/08/20246:00AMGlobeNewswire Inc.Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
03/08/20249:00AMGlobeNewswire Inc.Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
03/04/20245:21PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYMRKymera Therapeutics Inc
03/04/20245:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYMRKymera Therapeutics Inc
03/04/20245:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYMRKymera Therapeutics Inc
03/04/20244:50PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KYMRKymera Therapeutics Inc
03/04/20244:47PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KYMRKymera Therapeutics Inc
02/28/20246:00AMGlobeNewswire Inc.Kymera Therapeutics to Participate in Upcoming March Investor ConferencesNASDAQ:KYMRKymera Therapeutics Inc
02/27/20243:22PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KYMRKymera Therapeutics Inc
02/22/20246:32AMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:KYMRKymera Therapeutics Inc
02/22/20246:10AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KYMRKymera Therapeutics Inc
02/22/20246:00AMGlobeNewswire Inc.Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business UpdateNASDAQ:KYMRKymera Therapeutics Inc
02/15/20246:00AMGlobeNewswire Inc.Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22NASDAQ:KYMRKymera Therapeutics Inc
02/09/20246:47PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYMRKymera Therapeutics Inc
02/09/20243:22PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KYMRKymera Therapeutics Inc
01/31/20246:00AMGlobeNewswire Inc.Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare ConferenceNASDAQ:KYMRKymera Therapeutics Inc
01/09/20248:17AMGlobeNewswire Inc.Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology ProgramsNASDAQ:KYMRKymera Therapeutics Inc
01/09/20248:15AMGlobeNewswire Inc.Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:KYMRKymera Therapeutics Inc
01/05/20243:11PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KYMRKymera Therapeutics Inc
01/05/20243:02PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KYMRKymera Therapeutics Inc
01/05/20245:00AMGlobeNewswire Inc.Kymera Therapeutics Announces Pricing of $275 Million Public OfferingNASDAQ:KYMRKymera Therapeutics Inc
01/04/20243:06PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KYMRKymera Therapeutics Inc
01/04/20243:01PMGlobeNewswire Inc.Kymera Therapeutics Announces Proposed Public OfferingNASDAQ:KYMRKymera Therapeutics Inc
01/04/20246:08AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KYMRKymera Therapeutics Inc
01/04/20246:00AMGlobeNewswire Inc.R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory DiseasesNASDAQ:KYMRKymera Therapeutics Inc
01/02/20244:43PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYMRKymera Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KYMR

Your Recent History

Delayed Upgrade Clock